Anne Connolly
Neurology with Special Qualifications in Child Neurology · Columbus, OHNPI 1063438380
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $111,405 of the $153,862 with a category attached, or 72.4%. Sarepta Therapeutics, Inc. accounts for 63.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $37,007 and has fallen 71.7% since, to $10,465 in 2025. Among neurology with special qualifications in child neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $932.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$97K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$35K
- Genentech USA, Inc.$13K
- Genentech, Inc.$7K
- Mallinckrodt Enterprises LLC$2K
- Catalyst Pharmaceuticals, Inc.$45
Across 968 payments — averaging $4185.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$3.6M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$278K
- Novartis$141K
- Pfizer$29K
- Hoffmann-la Roche Limited$23K
- PTC Therapeutics, Inc.$3K
- plus $699 from 2 others
What the payments were for
- Consulting fees$111,40572%
- Speaking & faculty fees$11,4967%
- Travel & lodging$5,1583%
- Food & beverage$2,3122%
- Education$23,49015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 56 | $97,186 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 94 | $34,942 |
| Genentech USA, Inc. | 11 | $12,725 |
| Genentech, Inc. | 1 | $6,900 |
| Mallinckrodt Enterprises LLC | 1 | $2,064 |
| Catalyst Pharmaceuticals, Inc. | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$33,965
- Exondys 51$12,540
- Elevidys$10,465
- Non-Covered Product$7,304
- EVRYSDI$5,245
How this compares
$153,862 in reported general payments places this provider in the 95th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.
See all neurology with special qualifications in child neurology providers in Ohio →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ViltepsoViltolarsen | 17 | $1,636,264 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Columbus
- Emily DelosreyesColumbus$79K
- Samiah Al-ZaidyColumbus$70K
- Ann PakalnisColumbus$56K
- Diana Bharucha-GoebelColumbus$40K
- Megan WaldropColumbus$40K
- Sylvia AwadallaColumbus$39K
- Kevin FlaniganColumbus$24K
- Anup PatelColumbus$14K
- Kelsey PoissonColumbus$13K
- Melissa ChungColumbus$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.